| Catalog No. | HF831016 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Human |
|---|
| Isotype | IgG1-lambda |
|---|
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
C4.4A, Matrigel-induced gene C4 protein, GPI-anchored metastasis-associated protein C4.4A homolog, MIG-C4, LYPD3, Ly6/PLAUR domain-containing protein 3 |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
O95274 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | BAY1112623, BAY1129980, 1640971-88-5 |
|---|
| Background | Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980.
• LY6/PLAUR domain containing 3 (LYPD3) maintains melanoma cell stemness and mediates an immunosuppressive microenvironment., PMID:37924160
• m6A-dependent mature miR-151-5p accelerates the malignant process of HNSCC by targeting LYPD3., PMID:39009906
• LY6/PLAUR domain containing 3 has a role in the maintenance of colorectal cancer stem-like cells., PMID:28238780
• CircCBFB-mediated miR-28-5p facilitates abdominal aortic aneurysm via LYPD3 and GRIA4., PMID:32151690
|
|---|
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
